| External factors: | TPA |
| Aging type: | Prevent |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Aging |
| Experiment: | SA-β-gal activity assay//Western blot//Immunostaining//Cell Cell proliferation assay |
| Description: | Nuclear translocation of pErk1/2 by TPA treatment was accompanied with significant reductions of senescence markers in HDF old cells; over 10% decrease of SA-β-gal activity, and 50% decrease of p53 and p21WAF1expressions. Furthermore, treatment of old cells with TPA significantly reduced senescence markers such as PML body formation, and expressions of 53BP1 and H3K9me2,as opposed to no response in young cells;Treatment of HDF mid-old cells with TPA exhibited much more significant cell proliferation than that of the DMSO treated cells. |
| Target gene: | PERK1/2 |
| R-EF-Target gene: | -- |
| Official symbol(s): | MAPK1 |
| Target gene experiment: | Immunocytochemistry |
| Target gene description: | TPA co-treatment further increased the effect of siPEA-15 transfection compared with other treatments. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: